Loading...
01/11 17:03
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call reveals strong financial performance with a 21% revenue growth YoY and strategic partnerships, including a 20-year collaboration with Google Health. The transition to a SaaS model and international expansion plans signal positive future prospects. Despite challenges in short-term cash flow visibility, the company's strategic moves, like expanding cloud ARR and backlog growth, are promising. The Q&A highlights positive sentiment towards subscription models and product updates. Overall, the positive developments outweigh the concerns, suggesting a positive stock price movement in the short term.
Total Revenue $4.2 million, an increase of $0.1 million, or 4% year-over-year. The increase is attributable to key deals and the expanded sales team.
Product Revenue $2.5 million, up 14% year-over-year.
Service Revenue $1.7 million, down 9% year-over-year. This decline was largely driven by service customers migrating to subscription or cloud products.
Gross Profit $3.6 million, compared to $3.5 million last year, with a gross profit margin of 86%, consistent with Q3 2023.
Total Operating Expenses $5.6 million, a $0.9 million or 19% year-over-year increase, driven by investments in R&D and regulatory support.
GAAP Net Loss $1.8 million, or $0.07 per diluted share, compared to a net loss of $1 million, or $0.04 per diluted share for Q3 2023.
Non-GAAP Adjusted EBITDA Loss $1.5 million, compared to $0.8 million in Q3 2023.
Cash and Cash Equivalents $18.8 million as of September 30, 2024, down from $21.7 million as of December 31, 2023.
Net Cash Used for Operating Activities $2.6 million for the nine months ended September 30, 2024, compared to $3.5 million for the same period in 2023, an improvement of 26% year-over-year.
Total Annual Recurring Revenue (T-ARR) $9.3 million as of September 30, 2024, up from $8.4 million in Q3 2023.
Maintenance Services ARR (M-ARR) $6.7 million, down from $7 million at the end of Q3 2023, due to service customers migrating to subscription or cloud products.
Subscription ARR (S-ARR) $2.2 million, up from $1.4 million at the end of Q3 2023.
Cloud ARR (C-ARR) $0.4 million, representing the accumulation of the first two quarters of recurring revenue from the cloud product.
Total Orders Closed Closed 52 perpetual, 20 subscription, and 13 cloud orders in Q3 2024.
ProFound Detection Version 4.0: FDA clearance for ProFound Detection Version 4.0, offering a 22% improvement in detecting challenging cancers and an 18% reduction in false positives.
ProFound Cloud: Launch of ProFound Cloud, a software-as-a-service model, enabling scalable updates and creating a high-margin recurring revenue stream.
Global Expansion: Expansion into over 50 countries, with new distribution alliances in Dominican Republic, France, Spain, Turkey, UAE, and regulatory clearance in South Africa.
New Deals: Closed 85 deals in Q3, including significant contracts with UCSD and Charlotte Radiology.
Operational Efficiency: ProFound Cloud processed over 100,000 cases in its first two quarters, achieving processing speeds more than 50% faster than traditional solutions.
Customer Migration: Existing customers migrating to cloud solutions, enhancing service agreements and operational efficiency.
Shift to SaaS: Strategic shift to a software-as-a-service model, impacting revenue recognition and cash flow in the short term but expected to drive long-term growth.
Regulatory Issues: The FDA requires all mammogram reports in the U.S. to include a breast density assessment, which may lead to challenges related to insurance coverage and access to additional screening modalities.
Transition to SaaS Model: The shift from a perpetual revenue model to a software-as-a-service (SaaS) model may result in lower GAAP revenue and negative cash flow in the short term, as revenue recognition will occur over the term of the agreement rather than upfront.
Competitive Pressures: Despite having a market-leading position, AI adoption in mammography remains low at approximately 37% of U.S. sites, indicating competitive pressures as the company seeks to expand its market share.
Economic Factors: The ongoing economic environment may impact customer spending and investment in new technologies, which could affect the company's growth and revenue projections.
Supply Chain Challenges: As the healthcare landscape shifts towards technology as a service models, the complexity of setting up and upgrading specialized hardware and software may pose supply chain challenges.
Cash Flow Visibility: The transition to a recurring revenue model may lead to short-term fluctuations in cash flow visibility and predictability, impacting financial planning.
Transformation Strategy: Continued progress with the transformation strategy, including the transition to cloud or software-as-a-service through the growth of the ProFound Cloud platform.
AI Market Position: iCAD is positioned in the AI powered breast cancer detection market, with solutions backed by over 50 clinical studies and key global clearances.
ProFound Detection Version 4.0: FDA clearance for ProFound Detection Version 4.0, offering a 22% improvement in detecting challenging cancers and an 18% reduction in false positives.
Global Expansion: Expansion into new markets including Dominican Republic, France, Spain, Turkey, UAE, and collaborations in South Africa.
Cloud Transition: Shift to a software-as-a-service model, enabling scalable updates and creating a high-margin recurring revenue stream.
Customer Migration: Existing customers migrating to cloud solutions, enhancing long-term revenue stability.
Revenue Expectations: Top line revenue may flatten or drop in the short-term due to the transition to cloud-based revenue recognition.
Annual Recurring Revenue (ARR): Total ARR was $9.3 million as of September 30, 2024, up from $8.4 million in Q3 2023.
Short-term Impact on Revenue: Intentionally sacrificing immediate recognition of some GAAP revenue and cash flow during the transition.
Long-term Revenue Stability: Expecting stronger economic returns and more predictable revenue as recurring revenue builds.
Backlog Contribution: 13 cloud deals closed in Q3 add more than $850,000 to backlog for both billings and GAAP revenue.
Cloud ARR: Cloud ARR or C-ARR was $0.4 million, representing the accumulation of the first two quarters of recurring revenue from our cloud product.
Total ARR: Total ARR OR T-ARR was $9.3 million as of September 30, 2024, up from $8.4 million in the third quarter of 2023.
Subscription ARR: Subscription ARR OR S-ARR was $2.2 million, up from $1.4 million at the end of the third quarter of 2023.
Backlog from Cloud Deals: The 13 cloud deals closed in Q3 add more than $850,000 to our backlog for both billings and GAAP revenue.
Revenue Recognition Example: Assume a perpetual deal is worth $36, with perpetual we recognize revenue and bill all $36 upfront. Compare that to a $36 three-year cloud deal. With cloud we recognize revenue and collect cash over the term of the agreement.
Revenue for Q3 2024: Revenue for the quarter was $4.2 million, an increase of $0.1 million, or 4% over the third quarter of 2023.
The earnings call highlights several negative factors: declining occupancy rates, adverse rental income trends, refinancing concerns, competitive pressures, and regulatory uncertainties. While there are positives like a strong liquidity position and positive reversion in light industrial leases, the overall sentiment is cautious. The Q&A section confirms these concerns, with management acknowledging challenges in refinancing and uncertain political conditions. Given the mixed financial performance and cautious guidance, the stock is likely to experience a negative reaction in the short term.
The earnings call presents a mixed outlook. There are positives like strong deal growth and cloud transition, but concerns about increased operating expenses and a wider net loss. The Q&A section highlights uncertainties, such as the impact of new regulations and the transition timeline for existing customers. The market's reaction may be muted as the company navigates these challenges, especially without clear guidance on key issues. Given these factors, the stock price is likely to remain stable in the short term.
The earnings call reveals strong financial performance with a 21% revenue growth YoY and strategic partnerships, including a 20-year collaboration with Google Health. The transition to a SaaS model and international expansion plans signal positive future prospects. Despite challenges in short-term cash flow visibility, the company's strategic moves, like expanding cloud ARR and backlog growth, are promising. The Q&A highlights positive sentiment towards subscription models and product updates. Overall, the positive developments outweigh the concerns, suggesting a positive stock price movement in the short term.
The earnings call reveals several concerns: the transition to a recurring revenue model is expected to negatively impact short-term GAAP revenue and cash flow, and there are risks related to market penetration, regulatory challenges, and competitive pressures. Although there is a 21% revenue increase, the absence of a share repurchase program and unclear management responses in the Q&A section add to the negative sentiment. Despite some positive financial metrics, the overall outlook suggests a negative stock price movement.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
